Mastrangelo M J, Sulit H L, Prehn L M, Bornstein R S, Yarbro J W, Prehn R T
Cancer. 1976 Feb;37(2):684-92. doi: 10.1002/1097-0142(197602)37:2<684::aid-cncr2820370212>3.0.co;2-y.
The therapeutic efficacy of intralesional BCG (Bacillus Calmette-Guerin; one immunizing dose every 2 weeks for a minimum of five treatments) was studied in 19 melanoma patients. Of 15 patients evaluable for response, five experienced significant objective improvement (two complete and three partial remissions). Objective improvement was limited to those patients with dermal metastatic disease. In vitro cytotoxicity in the presence of patient's serum bore, on average, a relationship to the clinical disease. In certain individual cases, serum blocking and/or lymphocyte stimulation may have had prognostic significance.
对19例黑色素瘤患者研究了病灶内注射卡介苗（Bacillus Calmette-Guerin；每2周注射一次免疫剂量，至少注射5次）的治疗效果。在15例可评估反应的患者中，5例有明显的客观改善（2例完全缓解，3例部分缓解）。客观改善仅限于有皮肤转移疾病的患者。在患者血清存在的情况下，体外细胞毒性平均与临床疾病有关。在某些个别病例中，血清阻断和/或淋巴细胞刺激可能具有预后意义。
